Nivolumab in combination with ipilimumab for the treatment of melanoma
- 24 September 2015
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Anticancer Therapy
- Vol. 15 (10) , 1135-1141
Abstract
Melanoma patients develop resistance to most therapies, including chemo- and targeted-therapy drugs. Single-agent therapies are ineffective due to the heterogeneous nature of tumors comprising seve...Keywords
This publication has 58 references indexed in Scilit:
- Single Institution Experience of Ipilimumab 3 mg/kg with Sargramostim (GM-CSF) in Metastatic MelanomaCancer Immunology Research, 2015
- Evolving synergistic combinations of targeted immunotherapies to combat cancerNature Reviews Cancer, 2015
- The Evolving Role of Immune Checkpoint Inhibitors in Cancer TreatmentThe Oncologist, 2015
- Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunityNature, 2015
- Chimeric Antigen Receptor T Cells for Sustained Remissions in LeukemiaNew England Journal of Medicine, 2014
- Update on benefit of immunotherapy and targeted therapy in melanoma: the changing landscapeCancer Management and Research, 2014
- Pathways and therapeutic targets in melanomaOncotarget, 2014
- Nivolumab plus Ipilimumab in Advanced MelanomaNew England Journal of Medicine, 2013
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging studyThe Lancet Oncology, 2010